SAN FRANCISCO (EGMN) - The addition of rituximab to the standard chemotherapy regimen of fludarabine and cyclophosphamide significantly improves progression-free survival in patients with advanced chronic lymphocytic leukemia, according to two large randomized phase III trials.The triple therapy, called FCR, proved superior both in previously untreated patients and in those with relapsed or refractory chronic lymphocytic leukemia (CLL), the most common form of adult leukemia in the United States....